Taysha Gene Therapies, Inc. 8-K

What Happened
Taysha Gene Therapies, Inc. announced on June 24, 2026 that it entered an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC to sell 32,500,001 shares of common stock and pre-funded warrants to purchase 833,333 shares in an underwritten public offering. The public offering price is $6.00 per common share (and $5.999 per pre-funded warrant). The underwriters will buy the securities from Taysha at $5.64 per share and $5.639 per pre-funded warrant. The offering is expected to close June 26, 2026, and the company granted the underwriters a 30‑day option to buy up to an additional 5,000,000 shares.

Key Details

• Offering size: 32,500,001 common shares plus pre-funded warrants to purchase 833,333 shares; underwriters can purchase up to 5,000,000 more shares within 30 days.
• Pricing: $6.00 per common share; $5.999 per pre-funded warrant; underwriter purchase price $5.64 / $5.639 respectively.
• Estimated net proceeds: approximately $187.4 million (or about $215.6 million if the option is fully exercised), after underwriting discounts, commissions and expenses.
• Pre-funded warrants: $0.001 initial exercise price; exercise subject to ownership limits (generally 4.99% or 9.99%, with a holder able to adjust up to 19.99% with 61 days’ notice).
• Company statement: believes proceeds plus existing cash will fund operations into the second half of 2028.

Why It Matters
This offering is a capital raise that should materially increase Taysha’s cash resources and extend its reported runway into mid/late 2028, reducing near-term financing risk. For investors, the issuance will dilute existing shareholders (and could dilute further if the underwriters’ option is exercised). The inclusion of pre-funded warrants lets some buyers avoid immediate dilution while enabling near-zero exercise price conversion subject to ownership caps. The filing also includes standard legal opinions and forward-looking disclaimers; completion of the offering is subject to customary closing conditions.